Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (265)	3/22/1998 11:20:00 PM
From: Boyce Burge	Read Replies (2) \| Respond to of 4474

Im a little vague myself, but its basically a suite of genes that could be introduced into an embryonic cell and eventually find itself in most cells or every cell of an organism. It could be turned on or off by a small molecule and could control such events as aging-related changes, or whatever can be controlled by an introduced gene. Though this is pie in the sky today as far as humans go, it is very feasible in animal models and in fact there was a conference on the subject at UCLA this weekend. ARIAs strategy for turning on or off introduced genes is similar to this germline-cassete concept, although not currently targeted at germ cells (not yet!). You will have to hold your ARIA shares for a long time to see the $$ benefits of this, I'm afraid.